United States Patent 7,803,788: What Is Claimed, What Is Protected, and Where the Landscape Stands

United States Patent 7,803,788 claims antiviral therapy methods that dose diastereomerically enriched compounds with narrowly defined stereochemical impurity limits (by weight), where the active is defined by general formulae (structures (3), (5a), (6), (7)) that incorporate: (i) a hydrolyzable oxyester or hydroxyl substituent at a defined position (R1), (ii) a heterocyclic base (B), (iii) a phosphorus-containing unit described via P substituent constraints (R2 or amino-acid-linked P through amino group), and (iv) a substituent-defined carbon linker space (E) that ties the structural scaffold to the base. Dependent claims drive purity tighter from <40% down to <20% and <5% of a disfavored diastereomer.

What do the independent claims cover?

Claim 1: Method of antiviral therapy with diastereomer impurity limits

Claim 1 is the broadest anchor. It covers a method for antiviral therapy by administering a therapeutically effective amount of a diastereomerically enriched compound that:

Has structure (3), containing <40% by weight of diastereomer (4).
Has substituent logic that is tightly structural but still broad in the definition space:
- R1 is an oxyester hydrolyzable in vivo or hydroxyl.
- B is a heterocyclic base.
- R2 is either:
- hydroxyl, or
- the residue of an amino acid bonded to the P atom through an amino group, where each carboxy substituent is optionally esterified,
- But not both R1 and R2 are hydroxyl.
- E is one of several allowed linkers (examples shown in the claim as a discrete set):
  —(CH2)2—, —CH(CH3)CH2—, —CH(CH2F)CH2—, —CH(CH2OH)CH2—, —CH(CH═CH2)CH2—, —CH(C═CH)CH2—, —CH(CH2N3)CH2—, —CH(R6)OCH(R6′)—, —CH(R9)CH2O—, or —CH(R8)O—.
  The claim states the broken line indicates an optional double bond, and that the right-hand bond links E to the heterocyclic base.
- R4 and R5 are independently chosen from:
- hydrogen, hydroxy, halo, amino, or a C1–C5 substituent selected from acyloxy, alkyoxy, alkylthio, alkylamino, dialkylamino.
- R6 and R6′ independently are: H, C1–C6 alkyl, C1–C6 hydroxyalkyl, or C2–C7 alkanoyl.
- R7 independently is H, C1–C6 alkyl; or R7 together forms —O— or —CH2—.
- R8 is H, C1–C6 alkyl, C1–C6 hydroxyalkyl, or C1–C6 haloalkyl.
- R9 is H, hydroxymethyl, or acyloxymethyl.
The claim covers: salts, free base, and solvates.

Business meaning: Claim 1 is a method claim but tethered to specific stereochemical enrichment and a defined scaffold space. It is not “any antiviral”; it is antiviral therapy by dosing a very particular chemical class with steric and substituent restrictions.

Claim 2 and 3: Tightening stereochemical impurity

These depend on Claim 1 and reduce allowed presence of the disfavored diastereomer:

Claim 2: compound contains <20% by weight diastereomer (4).
Claim 3: compound contains <5% by weight diastereomer (4).

Business meaning: The patent forces accused infringers into a high bar on diastereomeric purity. If a competitor’s formulation has diastereomer (4) above 20% (or 5% for the higher dependents), it may avoid these narrower dependents, but still potentially land within Claim 1’s <40% boundary depending on structure match.

What additional independent claim space exists beyond Claim 1?

Claim 4: Method with alternative structure (5a) and a different substituent pattern

Claim 4 is another core independent method claim:

Antiviral therapy by administering therapeutically effective amount of a diastereomerically enriched compound of structure (5a).
Contains <40% by weight diastereomer (5b).
Substituent constraints shift from Claim 1’s R1/R2 logic to:
- R5 is methyl or hydrogen.
- R6 has broad selection (two alternative readings are embedded in the claim as disjunctive language):
- R6 independently is H, alkyl, alkenyl, alkynyl, aryl, or arylalkyl, or
- same set, but substituted with 1 to 3 substituents from a listed set (alkylamino variants, hydroxyl, oxo, halo, amino, alkylthio, alkoxy variants, aryloxy variants, haloalkyl, nitro/nitroalkyl, azido variants, alkylacyl variants, carboxyl, alkylacylamino).
- R7 is the side chain of any naturally occurring or pharmaceutically acceptable amino acid; if that side chain has a carboxyl, it can be optionally esterified with alkyl or aryl.
- R11 is amino, alkylamino, oxo, or dialkylamino.
- R12 is amino or H.
Covers salts, tautomers, free base, solvates.

Business meaning: Claim 4 expands the scaffold variants into an amino-acid side-chain-defined regime with broader R6 substitution tolerance. It also keeps the “diastereomer impurity by weight” structure, but with a different paired diastereomer set ((5a)/(5b)).

Claim 5 and 6: Tightening diastereomer impurity for structure (5a)

Claim 5: <20% by weight of diastereomer (5b).
Claim 6: <5% by weight of diastereomer (5b).

Claim 7: Structure (6) method claim without explicit impurity threshold in text provided

Claim 7 covers:

Antiviral therapy by administering therapeutically effective amount of a diastereomerically enriched compound of structure (6), and its salts, tautomers, free base, solvates.

Business meaning: In the excerpted claim text, Claim 7 does not include an explicit numeric impurity threshold. It still requires “diastereomerically enriched,” which is a functional limitation; enforcement will depend on how enrichment is defined in the patent specification or experimental embodiments, but that definition is not present in the claim excerpt provided here.

Claim 8 to 10: Structure (7) method with explicit impurity thresholds

Claim 8: method for antiviral therapy by administering therapeutically effective amount of compound of structure (7) containing <40% of diastereomer (7a).
Claim 9: dependent to Claim 8, <20% by weight of diastereomer (7a).
Claim 10: dependent to Claim 9, <5% by weight of diastereomer (7a).

Business meaning: This is a second numeric impurity ladder tied to a different structure family.

How the claims map to protection scope

1) Scaffold scope: general formula-driven

The claims are structured around:

A heterocyclic base (B),
A phosphorus-containing element with specific R substitution logic (notably in Claim 1 via hydroxyl vs amino-acid-to-P via amino group, and with optional esterification of carboxyl),
A defined carbon-linker segment E (Claim 1 gives explicit allowed E fragments),
Multiple optional substituent allowances on positions represented by R4/R5/R6/R6’/R7/R8/R9.

Practically, that structure definition does not look like “a single molecule patent.” It looks like a class patent over an antiviral scaffold family where stereochemistry drives differentiation between therapeutic candidates.

2) Purity scope: explicit diastereomer cutoffs

Across the excerpt, the patent uses three numerical gates:

<40% by weight of a specified diastereomer (Claim 1, 4, 8)
<20% by weight (Claim 2, 5, 9)
<5% by weight (Claim 3, 6, 10)

This is a classic litigation-relevant feature because it turns chemical manufacturing outcomes (diastereomer ratios) into patent infringement boundaries.

3) Prosecution-ready “method” claim form

All claims are methods for antiviral therapy. This creates:

Potential infringement by dosing, not only by sale of the compound.
A typical enforcement pathway where labeling, clinical use, or trial administration can be matched to the claimed method.

4) Form of compound covered

Each claim includes salts, free base, and solvates. Some include tautomers as well (Claim 4, 7, 8 through claim sets in excerpt). That increases the odds that form-factor variants remain within literal coverage.

What design-arounds are implied by the claim language

Diastereomer impurity thresholds

If a competing product can be produced with a diastereomer distribution that falls outside the specified “contains less than X% of diastereomer (4/5b/7a)” boundaries, it may avoid those claims depending on how “diastereomerically enriched” is interpreted and whether a different diastereomer becomes the “target disfavored diastereomer” under the patent’s definitions.

R1/R2 hydroxyl exclusivity (Claim 1)

Claim 1 states: not both of R1 and R2 are hydroxyl. A compound engineered so that both R1 and R2 are hydroxyl would fall outside Claim 1’s literal boundary, though it could still fall into Claims 4/7/8 depending on their different structural constraints.

Linker E constrained to specific enumerated options (Claim 1)

Claim 1 enumerates allowed E fragments. Avoiding those exact E definitions is a direct design-around for Claim 1 while still leaving Claims 4/7/8 as potential traps if those claims map to different structural cores.

Patent landscape: where this claims-type sits among competitors

Because the request is specifically for the scope and claims and patent landscape for US 7,803,788, the core landscape inference is about the claim strategy rather than identifying each co-pending or competing document in the world. From the claims excerpt alone, the patent’s competitive positioning is:

A) “Diastereomerically enriched” as the commercial differentiator

The patent is built around diastereomer enrichment and uses numeric impurity limits. This places it in the same competitive zone as:

patents that protect chiral/diastreomer-specific antiviral candidates,
process or intermediate patents that enable making a single enriched diastereomer,
follow-on patents that protect purity specifications rather than changing the core therapeutic target.

B) Broad substituent allowance while keeping stereochemistry as the lock

Claim 4’s R6 substitution options and Claim 1’s R4/R5/R6/R8/R9 ranges show typical broadening moves:

broaden chemical variability,
narrow by stereochemical ratio.

Competitors face a double burden: they must change scaffold substituents enough to avoid the general formula mapping while also controlling diastereomeric profile relative to the named “disfavored” diastereomers in the patent.

C) Method-of-use layer

Even if a compound falls within the chemical space, liability in method claims requires evidence that it is administered for antiviral therapy and in a therapeutically effective amount. That can be satisfied by clinical labeling or research protocol records, making this patent relevant even when manufacturing and final formulation are done by third parties.

Key infringement triggers inside the claims

Claim 1 triggers

A product is at risk under Claim 1 if it has:

A diastereomerically enriched compound meeting structure (3),
<40% by weight of the specified disfavored diastereomer (4),
R1 = hydrolyzable oxyester in vivo or hydroxyl,
B = heterocyclic base,
R2 = hydroxyl or amino-acid residue bonded to P via amino,
and R1/R2 are not both hydroxyl,
E = one of the enumerated fragments,
plus R4/R5 and R6/R6’/R7/R8/R9 meet the option lists.

Claim 4 triggers

A product is at risk under Claim 4 if it has:

diastereomerically enriched compound structure (5a),
<40% of disfavored diastereomer (5b),
R5 = methyl or H,
R7 corresponds to a natural/pharmaceutically acceptable amino acid side chain (with optional esterification if carboxyl present),
R6 allows broad alkyl/aryl/alkenyl/alkynyl scope with up to 3 selected substituents from the long list,
R11 and R12 match amino/alkylamino/oxo/H constraints.

Claim 8 triggers

A product is at risk under Claim 8 if it has:

diastereomerically enriched compound structure (7),
<40% of disfavored diastereomer (7a).

Claim set logic summary (numerical “purity ladder”)

Claim	Compound structure in excerpt	Diastereomer impurity limit (by weight)	Covered object type
1	(3)	<40% of diastereomer (4)	antiviral therapy method
2	depends on 1	<20% of diastereomer (4)	antiviral therapy method
3	depends on 1	<5% of diastereomer (4)	antiviral therapy method
4	(5a)	<40% of diastereomer (5b)	antiviral therapy method
5	depends on 4	<20% of diastereomer (5b)	antiviral therapy method
6	depends on 4	<5% of diastereomer (5b)	antiviral therapy method
7	(6)	no explicit numeric limit in excerpt	antiviral therapy method
8	(7)	<40% of diastereomer (7a)	antiviral therapy method
9	depends on 8	<20% of diastereomer (7a)	antiviral therapy method
10	depends on 9	<5% of diastereomer (7a)	antiviral therapy method

What this means for a competitive portfolio

If you are developing a follow-on product

The dominant differentiator for freedom-to-operate is likely not dose, but diastereomer control.
Purity targets below 20% and especially below 5% move you directly into dependent-claim territory if the compound structure maps.

If you are evaluating licensing or acquisition

Claim coverage is wide in substituent space but narrow in stereochemical outcome.
An acquired program’s manufacturing reproducibility on diastereomer ratios becomes a legal risk variable, not only a quality spec variable.

If you are planning a design-around

The claim includes multiple “structural escape routes” (R1/R2 hydroxyl exclusivity; enumerated E fragments; alternative scaffolds (5a) and (7) with their own substituent logic).
Any redesign must be evaluated across the entire claim family because Claim 1’s avoided substructure can be independently encompassed by Claims 4 or 8.

Key Takeaways

US 7,803,788 is a diastereomer-enriched antiviral method patent with explicit impurity cutoffs: <40%, <20%, and <5% by weight of specified disfavored diastereomers tied to multiple scaffold families (3), (5a), (6), (7).
The independent claim set is structurally broad via enumerated substituent ranges (notably R6 in Claim 4) while being narrowed by stereochemistry, plus key conditional constraints such as R1/R2 hydroxyl exclusivity (Claim 1).
The competitive landscape position is defined less by “a single molecule” and more by a manufacturing outcome (diastereomeric ratio) coupled to a heterocyclic-phosphorus-containing antiviral scaffold and method-of-use framing.
Freedom-to-operate hinges on simultaneous matching/mismatching across: (i) scaffold mapping, (ii) enumerated linker options, and (iii) diastereomer impurity by weight.

FAQs

1) Do these claims protect the compound itself or only the method of treatment?
They are method-of-treatment claims: they cover administering a therapeutically effective amount of a specified diastereomer-enriched compound for antiviral therapy, and they include coverage for salts/free base/solvates (and tautomers in some claims).

2) Which parts are most likely to drive infringement disputes?
The numeric diastereomer thresholds (<40%, <20%, <5% by weight) and the structural mapping of the scaffold variables (R1/R2, E, heterocyclic base B, and the amino-acid-linked P logic in Claim 1) are the highest-leverage elements.

3) Can a product avoid Claim 1 by changing R1 or R2?
Yes, Claim 1 includes a specific conditional: R1 and R2 are not both hydroxyl. Changing the hydroxyl status relative to that constraint is a direct escape route, though it does not automatically clear Claims 4/7/8.

4) If a competitor achieves <5% diastereomer impurity, does that increase infringement risk?
It increases risk for the dependent claims that expressly require <5% of the named disfavored diastereomer, assuming the chemical structure also falls within the corresponding scaffold family.

5) Why are there multiple independent claim structures (3), (5a), (6), (7)?
The patent uses multiple structural formula families to capture different analogs that still share the same core legal theme: antiviral therapy dosing of a diastereomerically enriched compound with controlled impurity levels.

References

[1] United States Patent No. 7,803,788. Claims 1-10 (as provided in the prompt).

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1301519	⤷ Start Trial	2016/014	Ireland	⤷ Start Trial
European Patent Office	1301519	⤷ Start Trial	PA2016009	Lithuania	⤷ Start Trial
European Patent Office	1301519	⤷ Start Trial	300803	Netherlands	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,803,788

Summary for Patent: 7,803,788